The National Institute for Health and Clinical Excellence has approved a new treatment for kidney cancer.
NICE has recommended Pazopanib as a first-line treatment for those with advanced kidney cancer in certain circumstances.
It has also been recommended for patients who have not previously had cytokine therapy and either remain active or only struggle with strenuous activity.
GlaxoSmithKline, which manufactures the drug, has agreed a discount on the list price with a possible future rebate linked to the outcome of a clinical trial.
Broadcaster James Whale, founder and chairman of the James Whale Fund for Kidney Cancer and a kidney cancer survivor, said: “Kidney cancer patients will find this approval of the cancer drug Pazopanib a great comfort.
“NICE has been fully aware that the mood of the government and the general public is that terminally ill cancer patients should not be denied cancer treatment and, after the farce surrounding the refusal of Everolimus earlier last year, some good news is long overdue.
“As someone who has been directly affected by kidney cancer, I understand just how imperative access to these life-prolonging drugs is.”
We’re going viral! Have you friends heard about the ‘seat on the board’ petition? Let’s ensure nurses are actively involved in the new commissioning consortia.